Comparison of overall survival between de novo and secondary acute lymphoblastic leukemia patients of different ages
The study focused on the survival rate in patients with acute lymphoblastic leukemia (ALL). A total of 8305 ALL patients undergoing chemotherapy from the SEER database. Included patients were divided into thede novo ALL group (n=7454) and sALL group (n=851). Results showed the decreased survival rate of ALL with aging. sALL patients (18-75 years) had poorer prognosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Jiansheng Zhong, Xiaoyang Yu, Xing Zhang Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Chemotherapy | Databases & Libraries | Hematology | Leukemia | Lymphoma | Myeloma | Study